catalyst
biosciences
receives
us
patent
factor
portfolio
engineered
proteases
south
san
francisco
globe
newswire
catalyst
biosciences
nasdaq
cbio
today
announced
united
states
patent
trademark
office
uspto
issued
us
patent
number
entitled
modified
membrane
type
serine
protease
polypeptides
methods
patent
covers
catalyst
portfolio
engineered
proteases
selectively
cleave
degrade
complement
factor
including
lead
candidate
cb
potential
treatment
dry
amd
currently
partnered
biogen
modified
proteases
inhibit
complement
activation
potential
treat
multiple
diseases
dysregulated
complement
activation
plays
role
newly
issued
patent
provides
protection
least
cb
demonstrates
power
protease
engineering
platform
focus
complement
cascade
plan
leverage
platform
expand
number
candidates
move
clinical
development
coming
years
said
nassim
usman
president
chief
executive
officer
catalyst
biosciences
catalyst
biosciences
catalyst
research
clinical
development
biopharmaceutical
company
focused
addressing
unmet
needs
rare
hematologic
disorders
protease
engineering
platform
includes
two
clinical
programs
hemophilia
research
program
engineering
subcutaneous
sq
complement
inhibitors
partnered
preclinical
development
program
biogen
dry
macular
degeneration
amd
product
candidates
generated
protease
engineering
platform
improved
functionality
potency
allow
sq
administration
recombinant
coagulation
factors
complement
inhibitors
high
activity
gene
therapy
constructs
less
frequently
dosed
intravitreal
therapeutics
advanced
product
candidate
marzeptacog
alfa
activated
marzaa
sq
fviia
entering
phase
registration
study
late
next
product
candidate
dalcinonacog
alfa
dalca
sq
fix
demonstrated
efficacy
safety
phase
clinical
trial
individuals
hemophilia
b
discovery
stage
factor
ix
gene
therapy
construct
cb
hemophilia
b
demonstrated
superiority
compared
padua
variant
preclinical
models
finally
global
license
collaboration
agreement
biogen
development
commercialization
factor
pegylated
cb
statements
press
release
contains
statements
involve
substantial
risks
uncertainties
statements
include
statements
catalyst
plans
move
new
product
candidates
clinical
development
coming
years
potential
benefits
products
based
catalyst
engineered
protease
platform
plans
enroll
first
patient
phase
registration
study
marzaa
late
potential
marzaa
dalca
effectively
therapeutically
treat
hemophilia
subcutaneously
superiority
cb
gene
therapy
candidates
company
collaboration
biogen
development
commercialization
pegylated
cb
potential
treatment
geographic
dry
macular
degeneration
actual
results
events
could
differ
materially
plans
intentions
expectations
projections
disclosed
statements
various
important
factors
could
cause
actual
results
events
differ
materially
including
limited
risk
trials
studies
may
delayed
result
virus
factors
trials
may
satisfactory
outcomes
additional
human
trials
replicate
results
earlier
trials
potential
adverse
effects
may
arise
testing
use
dalca
marzaa
including
generation
neutralizing
antibodies
observed
patients
treated
dalca
risk
costs
required
develop
manufacture
company
products
higher
anticipated
including
result
delays
development
manufacturing
resulting
factors
risk
biogen
terminate
catalyst
agreement
competition
risks
described
risk
factors
section
company
quarterly
report
filed
securities
exchange
commission
august
filings
securities
exchange
commission
company
assume
obligation
update
statements
except
required
law
contact
ana
kapor
catalyst
biosciences
investors
